Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 180 µg/ml - solution for injection - 180 mcg/ml - active: peginterferon alfa-2a 180 µg/ml excipient: acetic acid benzyl alcohol glacial acetic acid sodium acetate soln 10% polysorbate 80 sodium acetate trihydrate sodium chloride water for injection

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 270 µg/ml; ribavirin 200mg;  ;   - combination - 135µg/0.5ml + 200mg - active: peginterferon alfa-2a 270 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 360 µg/ml; ribavirin 200mg;  ;   - combination - 180µg/0.5ml + 200mg - active: peginterferon alfa-2a 360 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 6 miu/ml;   - solution for injection - 3miu/0.5ml - active: interferon alfa-2a 6 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 12 miu/ml;   - solution for injection - 6miu/0.5ml - active: interferon alfa-2a 12 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 18 miu/ml;   - solution for injection - 9miu/0.5ml - active: interferon alfa-2a 18 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

Bahrein - inglês - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

wael pharmacy - interferon - injection - 3

Bahrein - inglês - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

wael pharmacy - interferon - injection - 10

Bahrein - inglês - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

wael pharmacy - interferon - injection iv - 5

União Europeia - inglês - EMA (European Medicines Agency)

biogen netherlands b.v.  - interferon beta-1a - multiple sclerosis - immunostimulants, - avonex is indicated for the treatment of:patients diagnosed with relapsing multiple sclerosis (ms). in clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three years without evidence of continuous progression between relapses; avonex slows the progression of disability and decreases the frequency of relapses;patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite ms.avonex should be discontinued in patients who develop progressive ms.